Technical Analysis for CLDX - Celldex Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
CLDX closed up 7.41 percent on Thursday, January 17, 2019, on 1.52 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
|Weak or Absent||Down||Up||Up|
|See historical CLDX trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 17||Crossed Above 50 DMA||Bullish||0.00%|
|Jan 17||MACD Bullish Centerline Cross||Bullish||0.00%|
|Jan 17||Pocket Pivot||Bullish Swing Setup||0.00%|
|Jan 17||Calm After Storm||Range Contraction||0.00%|
|Jan 17||Upper Bollinger Band Walk||Strength||0.00%|
|Jan 17||Inside Day||Range Contraction||0.00%|
|Jan 17||Wide Bands||Range Expansion||0.00%|
|Jan 17||Up 3 Days in a Row||Strength||0.00%|
|Jan 17||Upper Bollinger Band Touch||Strength||0.00%|
|Jan 16||50 DMA Resistance||Bearish||7.41%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused precision targeted immunotherapy platform. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and CDX-011, an antibody-drug conjugate, which completed a randomized Phase IIb study for the treatment of advanced breast cancer. The company also has various earlier stage candidates in clinical development, such as CDX-1135, a molecule that inhibits a part of the immune system called the complement system; CDX-1127, a therapeutic fully human monoclonal antibody for cancer indications that is in Phase I study in patients with selected malignant solid tumors or hematologic cancers; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor, which completed Phase I study in healthy subjects; and CDX-1401, an antibody-targeted technology program for cancer indications that completed Phase I study in combination with toll-like receptor agonists poly-ICLC. Its preclinical product candidate includes CDX-014, a human monoclonal antibody-drug conjugate that targets TIM-1, a molecule that is expressed on renal and ovarian cancers with minimal expression in normal tissues. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Thomas Jefferson University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CLDX news...
|52 Week High||2.9|
|52 Week Low||0.183|
|200-Day Moving Average||0.5296|
|50-Day Moving Average||0.2768|
|20-Day Moving Average||0.2385|
|10-Day Moving Average||0.263|
|Average True Range||0.0262|
|Chandelier Exit (Long, 3 ATRs )||0.2414|
|Chandelier Exit (Short, 3 ATRs )||0.2616|
|Upper Bollinger Band||0.2974|
|Lower Bollinger Band||0.1796|
|Percent B (%b)||0.94|
|MACD Signal Line||-0.0074|
|Market Cap||37.22 Million|
|Num Shares||128 Million|
|Price-to-Earnings (P/E) Ratio||-0.27|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||0.34|
|Resistance 3 (R3)||0.33||0.32||0.33|
|Resistance 2 (R2)||0.32||0.31||0.32||0.32|
|Resistance 1 (R1)||0.30||0.30||0.31||0.31||0.32|
|Support 1 (S1)||0.27||0.28||0.28||0.28||0.26|
|Support 2 (S2)||0.26||0.27||0.26||0.26|
|Support 3 (S3)||0.24||0.26||0.25|
|Support 4 (S4)||0.25|